Synopsis
Synopsis
0
EU WC
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Eqvalan
2. Ivermectin
3. Ivomec
4. Mectizan
5. Mk 933
6. Mk-933
7. Mk933
8. Stromectol
1. Ivermectin
2. Dihydroavermectin B1a
3. 70288-86-7
4. 22,23-dihydroavermectin B1a
5. 70161-11-4
6. Ivermectin Component B1a
7. 71827-03-7
8. Avermectin H2b1a
9. 5-o-demethyl-22,23-dihydroavermectin A1a
10. Chebi:63941
11. 91y2202ouw
12. (2ae,4e,5's,6s,6'r,7s,8e,11r,13r,15s,17ar,20r,20ar,20bs)-6'-[(2s)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2h,7h-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-o-(2,6-dideoxy-3-o-methyl-alpha-l-arabino-hexopyranosyl)-3-o-methyl-alpha-l-arabino-hexopyranoside
13. Mk-933
14. (1r,4s,5's,6r,6'r,8r,10e,12s,13s,14e,16e,20r,21r,24s)-6'-[(2s)-butan-2-yl]-21,24-dihydroxy-12-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one
15. Ivermectin B1a-d2
16. C48h74o14
17. Unii-91y2202ouw
18. 22,23-dihydroavermectin B(1)a
19. Ncgc00163233-01
20. Ivermectin (ivm)
21. Ivm
22. Einecs 276-046-2
23. Dihydro Avermectin Bla
24. Brn 4643153
25. 22,23-dihydro-5-o-demethylavermectin A1a
26. H2b1a
27. Prestwick3_000156
28. Dsstox_cid_3181
29. Ivermectin (mk-0933)
30. Dsstox_rid_76909
31. Dsstox_gsid_23181
32. Bspbio_000292
33. Schembl312795
34. Bpbio1_000322
35. Chembl263291
36. Dtxsid8023181
37. Chebi:94551
38. Hms2089m09
39. Hms2095o14
40. Hms3712o14
41. Wca82703
42. Tox21_112034
43. Bdbm50409816
44. Mfcd30496678
45. S1351
46. Akos027470116
47. Ivermectin Component B1a [mi]
48. Zinc238808778
49. Zinc252286706
50. Ac-6014
51. Ccg-220156
52. Ncgc00186639-01
53. Ncgc00186639-03
54. As-14167
55. Bi166167
56. Cas-71827-03-7
57. Hy-126937
58. Ab00513813
59. Cs-0108408
60. 22,23-dihydroavermectin B1a; Ivermectin
61. Ab00513813-02
62. Ab00513813-03
63. Ab00513813_04
64. Avermectin A1a, 22,23-dihydro-5-o-demethyl-
65. 288i867
66. Ivermectin, Antibiotic For Culture Media Use Only
67. Q-201262
68. Brd-k24652731-001-02-7
69. Brd-k85554912-001-08-9
70. Q27132923
71. Ivermectin, British Pharmacopoeia (bp) Reference Standard
72. Ivermectin, European Pharmacopoeia (ep) Reference Standard
73. Ivermectin, United States Pharmacopeia (usp) Reference Standard
74. Ivermectin, Pharmaceutical Secondary Standard; Certified Reference Material
75. (2ae,4e,5's,6s,6'r,7s,8e,11r,13r,15s,17ar,20r,20ar,20bs)-6'-[(2s)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17
76. Clooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-o-(2,6-dideoxy-3-o-methyl-alpha-l-arabino-hexopyranosyl)-3-o-methyl-alpha-l-arabino-hexopyranoside
| Molecular Weight | 875.1 g/mol |
|---|---|
| Molecular Formula | C48H74O14 |
| XLogP3 | 4.1 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 8 |
| Exact Mass | 874.50785703 g/mol |
| Monoisotopic Mass | 874.50785703 g/mol |
| Topological Polar Surface Area | 170 Ų |
| Heavy Atom Count | 62 |
| Formal Charge | 0 |
| Complexity | 1680 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 20 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 3 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of rosacea
Antiparasitic Agents
Drugs used to treat or prevent parasitic infections. (See all compounds classified as Antiparasitic Agents.)
Insecticides
Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)
D - Dermatologicals
D11 - Other dermatological preparations
D11A - Other dermatological preparations
D11AX - Other dermatologicals
D11AX22 - Ivermectin
P - Antiparasitic products, insecticides and repellents
P02 - Anthelmintics
P02C - Antinematodal agents
P02CF - Avermectines
P02CF01 - Ivermectin
Details:
Stromectol-Generic (ivermectin) is a glutamate-gated chloride channel modulator, small molecule drug candidate, which is indicated for the treatment of patients with strongyloidiasis & onchocerciasis.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Stromectol-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Senores Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 26, 2024
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Senores Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's Laboratories and Senores Pharmaceuticals Launch Ivermectin Tablets in US
Details : Stromectol-Generic (ivermectin) is a glutamate-gated chloride channel modulator, small molecule drug candidate, which is indicated for the treatment of patients with strongyloidiasis & onchocerciasis.
Product Name : Stromectol-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 26, 2024
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rosacea.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 16, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Ivermectin 1% Cream and Soolantra (Ivermectin) 10 mg/g Cream
Details : Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rosacea.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The mdc-STM is an investigational three-month active injectable formulation of ivermectin using Medincell’s BEPO technology to fight malaria transmission.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: mdc-STM
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Unitaid
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Funding April 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Unitaid
Deal Size : $6.0 million
Deal Type : Funding
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
Details : The mdc-STM is an investigational three-month active injectable formulation of ivermectin using Medincell’s BEPO technology to fight malaria transmission.
Product Name : mdc-STM
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 15, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50
Details : Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 15, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The SAIVE study was conducted to support mdc-TTG program, whose objective is to provide prevention of Covid-19 infection for weeks or months with a single injection of a long-acting formulation of ivermectin based on MedinCell’s proprietary technology, BEPO®.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: mdc-STM
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 05, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The SAIVE study was conducted to support mdc-TTG program, whose objective is to provide prevention of Covid-19 infection for weeks or months with a single injection of a long-acting formulation of ivermectin based on MedinCell’s proprietary technology,...
Product Name : mdc-STM
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 05, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
This non-exclusive licence agreement, will enable MPP to support the identification of suitable partners for the development and commercialisation of mdc-STM, an injectable formulation of ivermectin with a three-month action-duration.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: mdc-STM
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: The Medicines Patent Pool
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 13, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : The Medicines Patent Pool
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : This non-exclusive licence agreement, will enable MPP to support the identification of suitable partners for the development and commercialisation of mdc-STM, an injectable formulation of ivermectin with a three-month action-duration.
Product Name : mdc-STM
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 13, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ivermectin is a Food and Drug Administration (FDA)-approved antiparasitic drug used to treat several neglected tropical diseases, including onchocerciasis, helminthiases, and scabies.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Dermatology Brand Name: Ivermectin-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 04, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Gets USFDA Nod for Ivermectin Cream
Details : Ivermectin is a Food and Drug Administration (FDA)-approved antiparasitic drug used to treat several neglected tropical diseases, including onchocerciasis, helminthiases, and scabies.
Product Name : Ivermectin-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 04, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Lyndra’s investigational long-acting oral biweekly ivermectin (LYN-163), enabled by Lyndra’s LYNX™ drug delivery platform, is being studied as a tool in the fight to eradicate malaria.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 09, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lyndra’s investigational long-acting oral biweekly ivermectin (LYN-163), enabled by Lyndra’s LYNX™ drug delivery platform, is being studied as a tool in the fight to eradicate malaria.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 09, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): Ivermectin,Balstilmab,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Yuan Yuan
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 08, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Balstilmab,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Yuan Yuan
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Violaine Desort-Hénin, DVM
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 31, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Violaine Desort-Hénin, DVM
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention
Details : Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 31, 2022

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Udderfast
Dosage Form : Cream
Dosage Strength : 10mg/g
Packaging :
Approval Date : 30-10-2025
Application Number : 2.02E+13
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Ivermectin \"Orion\"
Dosage Form : Tablet
Dosage Strength : 3mg
Packaging :
Approval Date : 25-08-2025
Application Number : 28107370725
Regulatory Info : Prescription
Registration Country : Denmark
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Ivermectin Orion
Dosage Form : Tablet
Dosage Strength : 3mg
Packaging :
Approval Date : 02-09-2025
Application Number : 2.03E+13
Regulatory Info : Approved
Registration Country : Sweden
Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Rosesolute
Dosage Form : Cream
Dosage Strength : 10mg/g
Packaging :
Approval Date : 30-10-2025
Application Number : 2.02E+13
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Marketed
Registration Country : Norway
Brand Name : Ivomec vet
Dosage Form : Paste
Dosage Strength : 18.7mg/g
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Ecomectin Vet.
Dosage Form : Oral Powder
Dosage Strength : 6mg/g
Packaging :
Approval Date : 26-02-2015
Application Number : 28105463714
Regulatory Info : Prescription
Registration Country : Denmark

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Soolantra
Dosage Form : Cream
Dosage Strength : 10mg
Packaging :
Approval Date : 20/12/2016
Application Number : 65561
Regulatory Info : Allowed
Registration Country : Switzerland

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Moldova
Brand Name : Soolantra®
Dosage Form : Cream
Dosage Strength : 10mg/g
Packaging :
Approval Date : 26-01-2022
Application Number :
Regulatory Info :
Registration Country : Moldova

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Marketed
Registration Country : Norway
Brand Name : Iverpraz vet
Dosage Form : Paste
Dosage Strength : 18.7mg; 140.3mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Noromectin Vet.
Dosage Form : Paste
Dosage Strength : 1.87%forhorses
Packaging :
Approval Date : 07-08-2002
Application Number : 28103329101
Regulatory Info : Prescription
Registration Country : Denmark

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
47
PharmaCompass offers a list of Ivermectin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ivermectin manufacturer or Ivermectin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ivermectin manufacturer or Ivermectin supplier.
A Ivermectin B1a manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ivermectin B1a, including repackagers and relabelers. The FDA regulates Ivermectin B1a manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ivermectin B1a API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ivermectin B1a manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Ivermectin B1a supplier is an individual or a company that provides Ivermectin B1a active pharmaceutical ingredient (API) or Ivermectin B1a finished formulations upon request. The Ivermectin B1a suppliers may include Ivermectin B1a API manufacturers, exporters, distributors and traders.
click here to find a list of Ivermectin B1a suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Ivermectin B1a DMF (Drug Master File) is a document detailing the whole manufacturing process of Ivermectin B1a active pharmaceutical ingredient (API) in detail. Different forms of Ivermectin B1a DMFs exist exist since differing nations have different regulations, such as Ivermectin B1a USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ivermectin B1a DMF submitted to regulatory agencies in the US is known as a USDMF. Ivermectin B1a USDMF includes data on Ivermectin B1a's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ivermectin B1a USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ivermectin B1a suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Ivermectin B1a Drug Master File in Japan (Ivermectin B1a JDMF) empowers Ivermectin B1a API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Ivermectin B1a JDMF during the approval evaluation for pharmaceutical products. At the time of Ivermectin B1a JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Ivermectin B1a suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Ivermectin B1a Drug Master File in Korea (Ivermectin B1a KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ivermectin B1a. The MFDS reviews the Ivermectin B1a KDMF as part of the drug registration process and uses the information provided in the Ivermectin B1a KDMF to evaluate the safety and efficacy of the drug.
After submitting a Ivermectin B1a KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ivermectin B1a API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Ivermectin B1a suppliers with KDMF on PharmaCompass.
A Ivermectin B1a CEP of the European Pharmacopoeia monograph is often referred to as a Ivermectin B1a Certificate of Suitability (COS). The purpose of a Ivermectin B1a CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ivermectin B1a EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ivermectin B1a to their clients by showing that a Ivermectin B1a CEP has been issued for it. The manufacturer submits a Ivermectin B1a CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ivermectin B1a CEP holder for the record. Additionally, the data presented in the Ivermectin B1a CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ivermectin B1a DMF.
A Ivermectin B1a CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ivermectin B1a CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Ivermectin B1a suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ivermectin B1a as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ivermectin B1a API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ivermectin B1a as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ivermectin B1a and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ivermectin B1a NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ivermectin B1a suppliers with NDC on PharmaCompass.
Ivermectin B1a Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ivermectin B1a GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Ivermectin B1a GMP manufacturer or Ivermectin B1a GMP API supplier for your needs.
A Ivermectin B1a CoA (Certificate of Analysis) is a formal document that attests to Ivermectin B1a's compliance with Ivermectin B1a specifications and serves as a tool for batch-level quality control.
Ivermectin B1a CoA mostly includes findings from lab analyses of a specific batch. For each Ivermectin B1a CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ivermectin B1a may be tested according to a variety of international standards, such as European Pharmacopoeia (Ivermectin B1a EP), Ivermectin B1a JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ivermectin B1a USP).